Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 5Motor Activity 3Weight Loss 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Smoking Cessation 1Neoplasms 1Metabolic Syndrome 1Malnutrition 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Mitomycin 4Carboplatin 4Sunitinib 3Pemetrexed 3dodecyl maltoside 2cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Diet × Genitourinary × Clear all
NCT03410641 2018-01-25

Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study

Oslo University Hospital

Completed
1,216 enrolled
GastrointestinalGenitourinaryThoracic

Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Urologic Neoplasms, Weight Loss, Smoking Cessation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡